Nature Medicine editorial expresses support for primary care trusts’ approach to the use of off-label Avastin for wet AMD

An editorial in the June issue of the journal Nature Medicine has voiced support for the Primary Care Trusts (PCT) of Southampton, Hampshire, The Isle of Wight and Portsmouth (SHIP) in their joint decision to encourage the use of bevacizumab (Avastin) for the treatment of age-related macular degeneration (AMD). The Nature Medicine editorial contributes to the on-going debate over the off-label use of Avastin over Lucentis, an almost identical drug approved in the US and UK for the treatment of wet AMD.